Literature DB >> 32268840

CMTM8 Is a Suppressor of Human Mesenchymal Stem Cell Osteogenic Differentiation and Promoter of Proliferation Via EGFR Signaling.

Chee Ho H'ng1,2, Esther Camp1,2, Peter J Anderson1,2,3, Andrew C W Zannettino1,4, Stan Gronthos1,2.   

Abstract

Multipotent bone marrow-derived mesenchymal stem/stromal cells (BMSCs) exhibit a finite life span after ex vivo expansion leading to cellular senescence. Many factors can contribute to this. Recently, our group has identified for the first time expression of the chemokine-like factor superfamily 8 (CMTM8) gene in cultured human BMSCs. In this study, we examine the role of CMTM8 in BMSC proliferation, migration, and differentiation. Functional studies using siRNA-mediated knockdown of CMTM8 in human BMSCs resulted in decreased capacity to undergo proliferation and migration and an increased capacity for osteogenic differentiation in vitro. Furthermore, reduced CMTM8 levels led to a decrease in the epidermal growth factor receptor (EGFR) signaling pathway during BMSC proliferation and migration, respectively. Supportive studies using retroviral mediated enforced expression of CMTM8 in BMSC resulted in an increased capacity for proliferation and migration but a decreased osteogenic differentiation potential. Collectively, these data suggest that CMTM8 promotes BMSC proliferation and BMSC migration through the EGFR/ERK1/2 pathway. This study provides insight into novel regulatory mechanisms of human BMSC growth and cell fate determination.

Entities:  

Keywords:  BMSC; CMTM8; bone; mesenchymal stem/stromal cell

Mesh:

Substances:

Year:  2020        PMID: 32268840     DOI: 10.1089/scd.2020.0007

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  2 in total

1.  Ex Vivo Culture of Human Cranial Suture Cells.

Authors:  Peter J Anderson
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Chemokine-Like Factor-Like MARVEL Transmembrane Domain-Containing Family in Hepatocellular Carcinoma: Latest Advances.

Authors:  Mengxia Li; Fangzhou Luo; Xinyao Tian; Shengyong Yin; Lin Zhou; Shusen Zheng
Journal:  Front Oncol       Date:  2020-11-13       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.